74 related articles for article (PubMed ID: 10651723)
1. Isolation and characterization of daunorubicin-resistant AML-2 sublines.
Choi CH; Ling V
Mol Cells; 1997 Apr; 7(2):170-7. PubMed ID: 9163728
[TBL] [Abstract][Full Text] [Related]
2. Importance of detecting multidrug resistance proteins in acute leukemia prognosis and therapy.
de Moraes AC; Maranho CK; Rauber GS; Santos-Silva MC
J Clin Lab Anal; 2013 Jan; 27(1):62-71. PubMed ID: 23292860
[TBL] [Abstract][Full Text] [Related]
3. Protein Kinase C Epsilon Overexpression Is Associated With Poor Patient Outcomes in AML and Promotes Daunorubicin Resistance Through p-Glycoprotein-Mediated Drug Efflux.
Nicholson R; Menezes AC; Azevedo A; Leckenby A; Davies S; Seedhouse C; Gilkes A; Knapper S; Tonks A; Darley RL
Front Oncol; 2022; 12():840046. PubMed ID: 35707351
[TBL] [Abstract][Full Text] [Related]
4. Discrimination of Multidrug Resistance in Cancer Cells Achieved Using Single-Cell Analysis.
Wang H; Zhang R; Yang D; Wang X
Methods Mol Biol; 2023; 2689():95-106. PubMed ID: 37430049
[TBL] [Abstract][Full Text] [Related]
5. Expression of P-glycoprotein, Cyclin D1 and Ki-67 in Acute Lymphoblastic Leukemia: Relation with Induction Chemotherapy and Overall Survival.
Elsayed GM; Ismail MM; Moneer MM
Indian J Hematol Blood Transfus; 2011 Sep; 27(3):157-63. PubMed ID: 22942566
[TBL] [Abstract][Full Text] [Related]
6. Systematic Review of Pharmacogenetics of ABC and SLC Transporter Genes in Acute Myeloid Leukemia.
Megías-Vericat JE; Martínez-Cuadrón D; Solana-Altabella A; Poveda JL; Montesinos P
Pharmaceutics; 2022 Apr; 14(4):. PubMed ID: 35456712
[TBL] [Abstract][Full Text] [Related]
7. Carbonyl reductase 1 expression influences daunorubicin metabolism in acute myeloid leukemia.
Varatharajan S; Abraham A; Zhang W; Shaji RV; Ahmed R; Abraham A; George B; Srivastava A; Chandy M; Mathews V; Balasubramanian P
Eur J Clin Pharmacol; 2012 Dec; 68(12):1577-86. PubMed ID: 22562609
[TBL] [Abstract][Full Text] [Related]
8. Association between P-glycoprotein and lymphoid antigen expression on myeloblasts versus therapy response and survival in de novo acute myeloid leukemia: long-term follow-up results.
Machaczka M; Wahlin BE; Piatkowska-Jakubas B; Rucinska M; Jurczak W; Balana-Nowak A; Klimkowska M; Hägglund H; Skotnicki AB
Med Oncol; 2012 Sep; 29(3):2070-6. PubMed ID: 21861206
[TBL] [Abstract][Full Text] [Related]
9. Molecular pharmacodynamics in childhood leukemia.
Pieters R; den Boer ML
Int J Hematol; 2003 Dec; 78(5):402-13. PubMed ID: 14704032
[No Abstract] [Full Text] [Related]
10. Subcellular daunorubicin distribution and its relation to multidrug resistance phenotype in drug-resistant cell line SMMC-7721/R.
Yang JY; Luo HY; Lin QY; Liu ZM; Yan LN; Lin P; Zhang J; Lei S
World J Gastroenterol; 2002 Aug; 8(4):644-9. PubMed ID: 12174371
[TBL] [Abstract][Full Text] [Related]
11. P-glycoprotein (PGP) and lung resistance-related protein (LRP) expression and function in leukaemic blast cells.
Michieli M; Damiani D; Ermacora A; Raspadori D; Michelutti A; Grimaz S; Fanin R; Russo D; Lauria F; Masolini P; Baccarani M
Br J Haematol; 1997 Feb; 96(2):356-65. PubMed ID: 9029025
[TBL] [Abstract][Full Text] [Related]
12. Novel mechanisms of drug resistance in leukemia.
Ross DD
Leukemia; 2000 Mar; 14(3):467-73. PubMed ID: 10720143
[TBL] [Abstract][Full Text] [Related]
13. Relationship of LRP-human major vault protein to in vitro and clinical resistance to anticancer drugs.
Izquierdo MA; Scheffer GL; Flens MJ; Shoemaker RH; Rome LH; Scheper RJ
Cytotechnology; 1996; 19(3):191-7. PubMed ID: 8862006
[TBL] [Abstract][Full Text] [Related]
14. P-glycoprotein and multidrug resistance-associated protein, but not lung resistance protein, lower the intracellular daunorubicin accumulation in acute myeloid leukaemic cells.
Borg AG; Burgess R; Green LM; Scheper RJ; Liu Yin JA
Br J Haematol; 2000 Jan; 108(1):48-54. PubMed ID: 10651723
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the clinical relevance of the expression and function of P-glycoprotein, multidrug resistance protein and lung resistance protein in patients with primary acute myelogenous leukemia.
Tsimberidou AM; Paterakis G; Androutsos G; Anagnostopoulos N; Galanopoulos A; Kalmantis T; Meletis J; Rombos Y; Sagriotis A; Symeonidis A; Tiniakou M; Zoumbos N; Yataganas X
Leuk Res; 2002 Feb; 26(2):143-54. PubMed ID: 11755464
[TBL] [Abstract][Full Text] [Related]
16. P-glycoprotein, lung resistance-related protein and multidrug resistance associated protein in de novo acute non-lymphocytic leukaemias: biological and clinical implications.
Michieli M; Damiani D; Ermacora A; Masolini P; Raspadori D; Visani G; Scheper RJ; Baccarani M
Br J Haematol; 1999 Feb; 104(2):328-35. PubMed ID: 10050716
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
